Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Ebvspecific T Cells Ebvctls

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed with results

Key Signals

2 with results100% success

Data Visualizations

Phase Distribution

3Total
Phase 1/2 (1)
Phase 2 (2)

Trial Status

Completed2
Withdrawn1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT00002663Phase 1/2Completed

Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

NCT01498484Phase 2Completed

Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

NCT03988582Phase 2Withdrawn

Safety and Effectiveness of EBV-specific Cytotoxic T Cells for the Treatment for EBV Lymphomas or Other EBV-associated Malignancies

Showing all 3 trials

Research Network

Common Treatments

  • Ebvspecific T Cells Ebvctls1
  • Epsteinbarr Virusspecific Cytotoxic T Lymphocytes Ebvctls1
  • Ebvspecific Tcells1

Active Sponsors

  • Memorial Sloan Kettering Cancer Center3
  • Atara Biotherapeutics2
  • National Cancer Institute (NCI)1

Top Investigators

Related Conditions

  • Ebvinduced Lymphomas2
  • Transplant Patients With Ebv Viremia At High Risk For Developing A Recurrent Ebv Lymphoma1
  • Ebv Lymphomas1
  • Transplant Patients With Ebv Viremia At High Risk Of Developing A Recurrent Ebv Lymphoma1

Activity Timeline